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Although our understanding of the molecular regulation of adult
neovascularization has advanced tremendously, vascular-targeted
therapies for tissue ischemia remain suboptimal. The master
regulatory transcription factors of the hypoxia-inducible factor
(HIF) family are attractive therapeutic targets because they co-
ordinately up-regulate multiple genes controlling neovasculariza-
tion.Here,weusedan induciblemodel of epithelial HIF-1 activation,
the TetON-HIF-1mouse, to test the requirement for VEGF in HIF-1me-
diated neovascularization. TetON-HIF-1, K14-Cre, and VEGFﬂox/ﬂox
alleleswere combined to create TetON-HIF-1:VEGFΔmice to activate
HIF-1 and its target genes in adult basal keratinocytes in the absence
of concomitant VEGF. HIF-1 induction failed to produce neovascula-
rization in TetON-HIF-1:VEGFΔmice despite robust up-regulation of
multipleproangiogenicHIF targets, includingPlGF, adrenomedullin,
angiogenin, and PAI-1. In contrast, endothelial sprouting was pre-
served, enhanced, and more persistent, consistent with marked re-
duction in Dll4-Notch-1 signaling. Optical-resolution photoacoustic
microscopy, which provides noninvasive, label-free, high resolu-
tion, andwide-ﬁeld vascular imaging, revealed the absence of both
capillary expansion and arteriovenous remodeling in serially im-
aged individual TetON-HIF-1:VEGFΔ mice. Impaired TetON-HIF-1:
VEGFΔ neovascularization could be partially rescued by 12-O-tetra-
decanoylphorbol-13-acetate skin treatment. These data suggest
that therapeutic angiogenesis for ischemic cardiovascular disease
may require treatment with both HIF-1 and VEGF.
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Neovascularization is crucial for solid tumor growth andmetastatic spread, for wound healing, and for tissue pres-
ervation and recovery after ischemia. Although tremendous
progress has been made in understanding the molecular circuits
regulating neovascularization in both benign and malignant dis-
ease, our knowledge remains incomplete. Solid tumors evade
angiogenesis inhibitors, and efﬁcacious therapeutic angiogenesis
for tissue ischemia remains a tantalizing prospect.
The hypoxia-inducible factors-1 and -2 (HIF-1 and HIF-2) are
αβ heterodimeric proteins that make crucial contributions to
neovascularization in wound healing, and benign or malignant
diseases (1, 2). HIFs are master regulatory transcription factors
with >100 known, and potentially hundreds more, target genes con-
taining the coreRCGTGenhancer sequence (3–6). A collection of
HIF target genes coordinates neovascularization at several levels
including endothelial cell proliferation, microvessel tone, vascular
remodeling, and proangiogenic myeloid cell recruitment (7).
Numerous reports suggested that HIF produced a more robust
neovasculature, with more normal structure and function, com-
pared with single angiogenic factor overexpression (2, 8–10).
However, the contribution of individual target genes encoding
vascular functions to the collective HIF-1 neovascular phenotype
is unknown. Here, we tested the hypothesis that VEGF was dis-
pensable for HIF-mediated neovascularization. We used a unique
conditional model of adult neovascularization in the skin, the
TetON-HIF-1 transgenic mouse (11) that displays multistage
neovascularization, and myeloid cell recruitment and retention in
the absence of disease. TetON-HIF-1 mice were engineered for
germ-line Cre-mediated VEGF deletion in the same basal kera-
tinocytes targeted for conditional adult HIF-1α induction. VEGF
deletion abrogated neovascularization despite coordinate up-
regulation of multiple angiogenic growth factors. Surprisingly,
endothelial sprouting was activated after HIF-1 induction; how-
ever, these sprouts were nonproductive for neovessel develop-
ment.Despite robust PlGF, adrenomedullin, andPAI-1 induction,
HIF-1 activation in the absence of VEGF failed to affect vascular
remodeling, and myeloid cell recruitment was markedly impaired.
Thus, we provide evidence that VEGF is required for HIF-1–
mediated adult neovascularization, but that certain elements of
the angiogenic response proceed without this factor.
Results
TetON-HIF-1:VEGFΔ Mice Lack Angiogenesis and Vessel Remodeling.
To test the role of VEGF during epithelial HIF-1–induced neo-
vascularization, we combined TetON-HIF-1 mice (11) with K14-
Cre transgenic and VEGF ﬂoxed (VEGFf/f) knock-in mice (12–
15). The ﬁnal genotype of these composite mice was K14-rtTA:
TRE-HIF-1αP402A/P564A/N803A:K14-Cre:VEGFf/f. This genotype,
designated as TetON-HIF-1:VEGFΔ, was n = 12 in the FVB/n
strain. Doxycycline (DOX) treatment of 8- to 12-wk-old TetON-
HIF-1:VEGFf/f mice induced a robust neovascularization that
peaked and plateaued 14 d after initiation (Fig. 1 A and B). In
contrast, neovascularization failed to occur in TetON-HIF-1:
VEGFΔ composite mice (Fig. 1 A and B). Moreover, contrary to
prior reports (16), there was no reduction ofmicrovascular density
in TetON-HIF-1:VEGFΔ composite mice, at baseline before
DOX induction compared with nontransgenic controls, likely due
to differences in tissue ﬁxation/epitope preservation techniques
and endothelial marker antibody detection reagents. Induction of
HIF-1α protein expression was detectable in both interfollicular
epidermal and hair follicle outer root sheath basal keratinocytes in
both TetON-HIF-1:VEGFΔ and TetON-HIF-1:VEGFf/f mice
after 14 days of DOX induction (Fig. 1C).
Temporal control of HIF-1 allowed us to deploy an emerging
technology for noninvasive and label-free functional deter-
mination of microvascular dynamics, optical-resolution photo-
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acoustic microscopy (OR-PAM) (17, 18). The resolving power
and image segmentation capabilities of OR-PAM enabled mul-
tiparameter determination of vascular morphology including
capillary volume as an indicator of angiogenesis, and arteriove-
nous (arteriolar/venular) volume, vessel length, diameter, and
tortuosity as measures of vascular remodeling. Because OR-
PAM uses hemoglobin for contrast (17), both the imaging and
quantitative segmentation analysis were based on perfused ves-
sels, which, similar to ante mortem lectin perfusion (10), is dis-
tinct from data derived from endothelial marker analysis of
postmortem tissue sections. Serial OR-PAM monitoring of in-
dividual mice from days 0 to 60 of continuous DOX provision
revealed that HIF-1 activation in TetON-HIF-1:VEGFf/f mice
produced an eightfold increase in capillary volume and a 3.5-fold
elevation of arteriovenous and overall vascular volume com-
pared with DOX-induced TetON-HIF-1:VEGFΔ or day 0
TetON-HIF-1:VEGFf/f controls (Fig. 2 A and Fig. S1B). OR-
PAM segmentation analysis suggested that capillary volume fell
between days 14 and 30 in the TetON-HIF-1:VEGFf/f mice (Fig.
S1). The difference between these data and the microvessel
density analysis based on CD31 decoration of all vessels could be
due to the lack of perfusion of CD31-positive vessels or that OR-
PAM acquires wide ﬁeld volumetric data and immunoﬂuores-
cence analyzes microvascular area in 2D tissue sections. OR-
PAM also demonstrated abrogation of HIF-1–mediated vasodi-
latation and tortuosity induction in the absence of epithelial
VEGF (Fig. S1B).
Loss of HIF-1–Induced VEGF Produces Sprouting Without Endothelial
Proliferation.Anoutstanding feature of theTetON-HIF-1model is
the ability to dissect discrete stages of neovascular network de-
velopment and its maintenance due to temporal control of HIF-1
gain of function (11). Here, we tested the necessity of VEGF for
HIF-1 induction of the earliest stages of neovascularization, en-
dothelial sprouting, and proliferation. DOX-treatedNTGand day
0 TetON-HIF-1:VEGFf/f mice were used interchangeably in all
studies, because they were phenotypically and functionally similar.
Endothelial proliferation remained at barely detectable levels af-
ter HIF-1 activation in TetON-HIF-1:VEGFΔmice, in contrast to
a robust induction in TetON-HIF-1:VEGFf/f counterparts (Fig.
S2A). Surprisingly, TetON-HIF-1:VEGFΔ mice evidenced a pro-
longed interval of endothelial sprouting up to day 14 duringHIF-1
induction (Fig. 3A, Left and Fig. S2B). In contrast, sprout elabo-
ration in TetON-HIF-1:VEGFf/f was restricted to the immediate
postinduction interval, markedly evident at DOXday 3, but nearly
undetectable by DOX day 14 (Fig. 3A, Left and Fig. S2B). Sprouts
were not detectable in NTG mice at any interval during DOX
treatment (Fig. 3A, Left and Fig. S2B). Because Dll4-Notch1 ac-
tivation regulates vascular sprouting, and is downstream of VEGF
signaling via VEGFR2 and VEGFR3 (19–21), we interrogated
mouse ear cross-sections for dual Dll4/CD31 coimmuno-
ﬂuorescence (Fig. 3A, Right). Endothelial Dll4 expression levels in
TetON-HIF-1:VEGFΔmice were low and similar to those of their
NTG counterparts up to 30 d of continuous HIF-1 induction (Fig.
3A, Right). In contrast, TetON-HIF-1:VEGFf/f mice evidenced
marked endothelial Dll4 up-regulation after 14 d of HIF-1 in-
duction (Fig. 3, Right Middle). We further explored Notch-1 sig-
naling by determining the expression kinetics and localization of
theNotch intracellular domain (NICD), the product of the gamma
secretase-mediated receptor cleavage and the active transcrip-
tional Notch component (22). The NICD was detectable in both
the day 14 TetON-HIF-1:VEGFf/f endothelium and in basal ker-
atinocytes (Fig. 3B, arrowheads). In contrast, the NICD was de-
tectable only in a few basal keratinocytes of TetON-HIF-1:
VEGFΔmice. The levels ofDll4 and the downstreamNotch target
Hey 1mRNAwere elevated 7- to 10-fold in TetON-HIF-1:VEGFf/f
mice compared with 14-d DOX-treated NTG controls (Fig. 3C).
Dll4 and Hey-1 were induced at low, but statistically signiﬁcant,
levels in TetON-HIF-1:VEGFΔ mice compared with NTG con-
trols (Fig. 3C). Collectively, these data suggest that HIF-1 and its
downstream targets (see below) are able to induce endothelial
sprouting, yet these sprouts are nonproductive in forming neo-
vessels in the absence ofVEGF.Thepaucity of epidermalNICD in
the TetON-HIF-1:VEGFΔ mice demonstrates that VEGF is re-
Fig. 1. Cre-mediated basal keratinocyte
VEGF deletion abrogated HIF-1–induced
neovascularization. (A) CD31 immuno-
ﬂuorescence (red) revealed robust neo-
vascularization in TetON-HIF-1:VEGFf/f
(VEGFf/f) compared with TetON-HIF-1:
VEGFΔ (VEGFΔ) mice, which remained
similar to baseline controls. DAPI was
used as a nuclear counterstain. (B) Quan-
titative analysis of CD31+ vascular area
revealed a threefold elevation in TetON-
HIF-1:VEGFf/f compared with TetON-HIF-
1:VEGFΔ mice induced with doxycycline
for similar time intervals (n = 3–6 mice
per time point). (C) Representative HIF-1α
transgene immunoﬂuorescence indicat-
ing localization to the epidermal and hair
follicle basal cell compartment after 14 d
of DOX induction. (B) VEGFΔ or VEGFf/f
data at each DOX day were compared with
VEGFf/f day 0 data by using the unpaired
Student’s t test (**P < 0.01 and ***P <
0.001). (Scale bars: A, 200 μm: C, 50 μm.)
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quired for robust Notch activation in this cellular tissue com-
partment after HIF-1 induction.
Induction of Multiple HIF-1 Angiogenic Target Genes Is Insufﬁcient for
Angiogenesis in the Absence of VEGF. Previous work has high-
lighted the angiogenic potential of several direct and indirect
HIF-1 transcriptional targets (23–29). To determine whether
these targets were induced by HIF-1 in the absence of VEGF,
whole skin extracts were analyzed by using RT-PCR, ELISA, or
antibody microarrays (Fig. 4 A and E). First, we determined the
functional efﬁciency of keratin-14 regulated Cre-mediated
VEGF deletion. Both mRNA and whole tissue ELISA revealed
baseline or even lower VEGF levels, compared with DOX-
treated NTG controls, despite HIF-1 induction.
Other targets exhibited four expression patterns. PIGF, angio-
genin, MMP-9, PAI-1, and MMP-3 were up-regulated in TetON-
HIF-1:VEGFΔ mice at levels comparable with TetON-HIF-1:
VEGFf/f controls (Fig. 4F and Fig. S3 A and B). Adrenomedullin
(ADM) and iNOS expression were lower in TetON-HIF-1:
VEGFΔ mice on DOX day 3, increased during continuous HIF-1
activation for 14 and 30 d, yet did not reach the levels evident in
TetON-HIF-1:VEGFf/f positive controls (Fig. 4 B and C). Car-
bonic anhydrase IX (CAIX) progressively increased in TetON-
HIF-1:VEGFΔ mice to levels comparable with TetON-HIF-1:
VEGFf/f positive controls by 30 d of continuous HIF-1 induction
(Fig. 4D). The fourth expression pattern tracked with VEGF ex-
pression, lack or markedly reduced induction in TetON-HIF-1:
VEGFΔ mice compared with marked up-regulation in TetON-
HIF-1:VEGFf/f counterparts. These molecules, osteopontin
(OPN), pentraxin-3 (PTX-3), cysteine-rich 61/connective tissue
growth factor/nephroblastoma overexpressed (CCN3/NOV), and
macrophage chemoattractant protein-1 (MCP-1), are expressed in
activated inﬂammatory and stromal ﬁbroblasts (30–32). Their
expression pattern was consistent with the marked diminution in
stromal myeloid cell recruitment and retention in TetON-HIF-1:
VEGFΔ compared with TetON-HIF-1:VEGFf/f mice (see below).
Epithelial VEGF Loss Markedly Impairs HIF-1–Mediated Myeloid Cell
Recruitment.HIF-1 is known to induce myeloid cell mobilization,
recruitment, and retention via VEGF, PlGF, and SDF1 (11, 33–36).
As such, we determined myeloid cell recruitment to HIF-1 stim-
ulated skin in the absence of concomitant VEGF. Surprisingly,
there was no signiﬁcant recruitment of CD45+, CD11b+, or
F4/80+ myeloid, or mast cells in TetON-HIF-1:VEGFΔ mice
after 14 d of HIF-1 induction despite signiﬁcant up-regulation
of the VEGFR1 ligand, PlGF (Figs. 4F and 5 A–C and Fig. S4).
By day 30, a signiﬁcant increase in both CD45 and CD11b myeloid
cells was achieved in TetON-HIF-1:VEGFΔ mice; however, these
myeloid cells were insufﬁcient to facilitate neovascularization in
the absence of epithelial VEGF (Fig. 5 A–C and Fig. S4). Myeloid
cell inﬁltration after chronic HIF-1 gain of function in DOX day
30 TetON-HIF-1:VEGFΔ mice was similar to our previous work
with germ-line skin-targeted constitutive HIF-1 mutants in trans-
genic mice (37). There, stromal myeloid cell trafﬁcking was reg-
ulated by chemokines not VEGF.
12-O-Tetradecanoylphorbol-13-Acetate (TPA)-Induced Inﬂammation
Produces Extensive Vascular Remodeling with Minimal Microvascular
Density Increase. Topical phorbol ester induces angiogenesis via
enhanced VEGF secretion from the activated epithelium (38,
39). Single-dose TPA treatment produces transient skin changes
resolving after 3–4 d in wild type mice. Previously, we discovered
that germ-line K14-HIF-1P402A/P564G transgenic mice responded
to single-dose TPA challenge with a marked and prolonged
stromal and intraepithelial neutrophil inﬁltrate persisting for 3
wk (37). Neutrophil recruitment was secondary to HIF-1–en-
hanced NFκB signaling and NFκB chemokine target gene up-
regulation by transgenic keratinocytes. We capitalized on this
strategy to determine whether the lack of HIF-1–mediated neo-
vascularization in TetON-HIF-1:VEGFΔ vasculature could
be rescued. TetON-HIF-1:VEGFΔ and TetON-HIF-1:VEGFf/f
were DOX-induced for 14 d to prime the keratinocytes and
stroma and emulate germ-line constitutive activation. One dose
of topical TPA was followed by ear harvest 10 d later. As re-
ported, TPA treatment produced a marked recruitment and re-
tention of CD45 stromal myeloid cells in TetON-HIF-1:VEGFf/f
mice (37), without affecting the frequency of CD11b macrophages
(Fig. S5 A and B). Both TPA-treated DOX day 14 TetON-HIF-1:
VEGFf/f and TetON-HIF-1:VEGFΔ mice ear epidermis was
similarly punctuated by microabscesses ﬁlled with neutrophils
(Fig. S6, Right), an observation consistent with our previous
ﬁndings (37). Moreover, TPA did not further augment VEGF
expression or neovascularization in TetON-HIF-1:VEGFf/f mice
(Fig. 6 A and B). In contrast, single-dose TPA in TetON-HIF-1:
VEGFΔ mice produced a twofold increase in VEGF expression
associated with a similar fold increase in neovessel area. TPA
also produced a similar inﬂux of neutrophils in TetON-HIF-1:
VEGFΔ mice (Fig. S5A, Left and B, Upper). Partial rescue of
Fig. 2. TetON-HIF-1:VEGFΔmice lacked vessel remodeling. (A) Angiogenesis determination and accompanying vascular remodeling by OR-PAM. OR-PAM was
performed in the same VEGFf/f or VEGFΔ transgenic mouse serially for 60 d (days 0–30 are represented). Increased capillary density (red asterisk) is evident
particularly by day 14, whereas arteriovenous remodeling (increase in vessel diameter and tortuosity) is detectable at day 14 and prominent by day 30 (blue
arrow) (see also Fig. S1). (Scale bar: 500 μm.)
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HIF-1–mediated neovascularization in TetON-HIF-1:VEGFΔ
mice was associated with expansion of an epidermal population
of unrecombined VEGFf/f alleles and abscess-derived neutro-
phils (Fig. S5B). However, VEGF expression was undetectable in
the majority of stromal neutrophils not associated with intra-
epidermal abcesses. TPA treatment also produced a statistically
signiﬁcant increase in capillary and total vessel volume, and
a trend towards an increase in vessel tortuosity, as determined by
OR-PAM (Fig. S7 A and B).
Discussion
In this study, we used a conditional mouse model to discover that
VEGF, among a repertoire of induced angiogenic target genes,
was necessary for HIF-1–mediated neovascularization. Targeting
Tet-regulatedHIF-1α to the skin had several advantages.Wewere
able to use unfurred ear skin, enabling visual assessment of neo-
vascular progression. The ear possessed a stereotypic histological
architecture with a sharply delineated boundary between the
transgene expressing basal keratinocytes and the underlying neo-
vessel and inﬂammatory cell containing stroma. These features
allowed us to determine alterations in tissue molecular signaling
and immunoﬂuorescent localization of induced signaling events
covering the entire spectrum of neovascularization, from initial
endothelial cell activation to development and maintenance of
a complete neovascular network. This combination of tissue or-
ganization for molecular expression localization and immediate
tissue sampling of an activated vasculature was distinct from dis-
ease models that required a lag phase to allow tumors to grow or
ischemic neovascularization to become established. Other studies
used adenoviral expression systems to create controlled time-
dependent ear neovascularization (40). This approach had two
challenges. First, there was an abrupt and massive overexpression
of angiogenic factors followed by rapid decline. Second, viral
particles were deposited in the stroma, an approach that did not
model angiogenic signaling from an activated epithelium that,
because it is initiated in the premalignant dysplasia, is an important
component of multistage epithelial carcinogenesis (41).
As expected, we detected DOX-induced up-regulation of mul-
tiple angiogenic target genes that could have compensated for
VEGF deﬁciency in TetON-HIF-1:VEGFΔmice. A lead example
was the indirect HIF target PlGF. PlGF binds and activates
VEGFR1 and induces phosphorylation of a repertoire of target
Fig. 3. Vessel sprouting increase with low-level increase of Notch activity in
VEGFΔmice. (A) Representative confocal CD31 immunoﬂuorescence showing
vessel sprouting in TetON-HIF-1:VEGFΔ and TetON-HIF-1VEGFf/f mice (arrows;
Left). Note multiple sprouts in VEGFΔ mice at DOX day 14 compared with
their absence in VEGFf/f mice. Representative dual Dll4/CD31 immunoﬂuo-
rescence (Right). VEGFf/f mice showed marked endothelial Dll4 upregulation
from 3 d of HIF-1 induction compared to VEGF δmice and NTG counterparts.
Sprouts were not detectable in DOX-treated NTG mice (Left). (B) Represen-
tative immunoﬂuorescence of cleaved Notch1 intracellular domain (NICD,
Val1744) in TetON-HIF-1:VEGFΔ and TetON-HIF-1VEGFf/f mice (arrows;Middle
and Bottom). (C) RT-PCR analysis (arbitrary units normalized to histone 3.3A)
of the Notch1 ligand Dll4 and downstream target Hey1 showing marked 7-
to 10-fold elevation in day 14 VEGFf/f mice (n = 3–4 mice per time point). In
contrast, Dll4 and Hey-1 were induced at low, albeit statistically signiﬁcant
levels in VEGFΔ mice. Data are mean ± SD. Statistical analysis was the un-
paired Student t test comparing each VEGFΔ or VEGFf/f DOX treatment day
to comparably treated NTG controls: *P < 0.05, **P < 0.01 and ***P < 0.001.
(Scale bars: A, Left, 20 μm; A, Right, 200 μm; B, 50 μm.)
Fig. 4. Induction of multiple HIF-1 angiogenic targets in TetON-HIF-1:VEGFΔ
mice. (A–D) RT-PCR determination (arbitrary unit normalized against histone
3.3A) of differential patterns of HIF-1 target gene mRNA expression. Adre-
nomedullin (ADM) and iNOS increased 2.4-fold by day 3 in VEGFΔ mice, but
further increased by sevenfold during continuous HIF-1 induction for 14 and
30 d, yet did not reach the induction levels of VEGFf/f positive controls. Sim-
ilarly, carbonic anhydrase IX (CAIX) progressively increased in VEGFΔ mice to
levels comparable to TetON-HIF-1:VEGFf/f positive controls by day 30 (n = 3–4
mice per time point). (E) Whole tissue ELISA revealed baseline or lower VEGF
levels in VEGFΔ mice, compared with DOX-treated NTG controls, during HIF-1
induction (n = 3 mice per time point). (F) PIGF was up-regulated in VEGFΔ
mice at similar levels as VEGFf/f controls (n = 3 mice per time point). Data
analyzed as in Fig. 1: *P < 0.05, **P < 0.01, and ***P < 0.001.
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proteins distinct fromVEGFR2 in endothelial cells (42, 43). PlGF
has been shown to amplify or inhibit VEGF signaling through
multiplemechanisms (44, 45). PlGFwas angiogenic when targeted
for overexpression in basal keratinocytes (23), or after local ade-
noviral injection in the skin or aortic adventitia (24, 25). PlGFgene
deletion or antibodies targeting PlGF inhibited tumor growth via
multiple mechanisms, including inhibition of angiogenesis, mye-
loid cell, and hematopoietic precursormobilization (24, 35, 36). In
models of tissue ischemia, PlGF was required for vascular di-
latation and collateralization (24, 46). Thus, we were surprised
that despite robust PlGF induction, angiogenesis, vascular di-
latation, arteriovenous remodeling, and myeloid cell recruitment
were unaffected by HIF-1 induction in the absence of VEGF. As
such, our work is consistent with theVEGF signaling ampliﬁcation
function of PlGF, but is in contrast to “direct” angiogenesis in-
duction of prior skin and adenoviral studies. The VEGF domi-
nance in our model is also in line with recent studies questioning
the contribution of PlGF to angiogenesis (47, 48).
In addition to PlGF, other angiogenic targets and vascu-
lar remodeling molecules were up-regulated in TetON-HIF-1:
VEGFΔ mice. The HIF target adrenomedullin was shown to pro-
mote physiological and pathological angiogenesis in vitro and in
animal models (49–51). ADM signals angiogenesis by binding
calcitonin-receptor-like receptor, which is widely expressed on
normal and hypoxic endothelial cells (49, 52). Angiogenin was
another molecule previously demonstrated to be angiogenic, yet
without consequence in TetON-HIF-1:VEGFΔ mice (28, 29). In
addition to these direct proangiogenic HIF targets, molecules
contributing accessory functions such asmatrix degradation and its
modulation, MMP9, MMP3, and PAI-1, and vascular dilatation,
iNOS, were also up-regulated in TetON-HIF-1:VEGFΔ mice.
Thus, many of the molecules in the angiogenic “toolbox” were el-
evated by HIF-1, yet all required coordinate VEGF up-regulation
to affect neovascularization and its modulation. Our data provide
additional insight into studies wherein deletion of the VEGF HIF
hypoxia response element (HRE) in ES cells or targeted germ-line
VEGF gene deletion in keratinocytes diminished tumor growth
(53) or delayed normal woundhealing (16), respectively.However,
in each of these studies, variable levels of neovascularization were
present, likely from compensatory angiogenic factors. Our use of
topical TPA challenge with its attendant prolonged stromal in-
ﬂammation and neovascularization rescue emulated disease-as-
sociated angiogenic compensation. We were surprised that the
VEGF increment induced by TPA in TetON-HIF-1:VEGFΔ
mice was not due to the numerous neutrophils inﬁltrating
throughout the stroma. Rather, the VEGF increment was local-
ized to the epidermis, likely due to expansion of a small pop-
ulation of preexisting basal keratinocytes with unrecombined
VEGFf/f alleles and to focal neutrophil accumulations beneath
intraepidermal abscesses. These data did not rule out a neovessel
activation function for the stromal neutrophils, which have been
shown in previous studies to be sources of compensatory angio-
genic factors such as FGF-2 in tumors during VEGF signaling
blockade (54). As such, our conditional model enabled precise
genetic dissection of “intrinsic” HIF-1 functions while enabling
titration of pathophysiological processes to test for complemen-
tation of baseline neovascularization deﬁciencies.
Finally, ear skin allowed us to continue to use an emerging
technique for determination of neovascular architecture and
microvessel function photoacoustic microscopy (PAM) (17).
PAM and the derivative used in our study, OR-PAM, use red
blood cell (RBC) hemoglobin for endogenous contrast. Dif-
fraction-limited optical focusing and exquisite (100%) sensitivity
to optical absorption enables single RBC resolution and capillary
resolution in vivo (18). Additionally, the wide ﬁeld of view of
OR-PAM enabled us to determine the necessity of VEGF for
both angiogenesis and arteriovenous remodeling in the context
of HIF-1 induction. These features plus simultaneous deter-
mination of multiple parameters of neovascular function and
tissue metabolism will be a boon for future studies in models of
neovascular disease (17).
In conclusion, we demonstrate that despite induction of multi-
ple angiogenic target genes, VEGF is necessary for HIF-1 medi-
ated neovascularization. The VEGF requirement can be sub-
stantially, although not entirely, rescued by chemokine-activated
keratinocytes and neutrophils accumulating adjacent to abscesses.
Recent studies have demonstrated provocative linkage between
age, cardiovascular disease, and insufﬁciency of HIF-1 expression
in both ischemic tissues and inﬁltrating myeloid cells (55, 56).
Because aging can also impair induction of VEGF expression
(57, 58), our work suggests that therapeutic angiogenesis may re-
quire combinatorial restoration or administration of both HIF-1
and VEGF to achieve optimal tissue neovascularization.
Materials and Methods
Mouse Development, Target Expression Analysis, Photoacoustic Microscopy,
and Inﬂammation Challenge. Detailed description of the mouse intercrosses to
generate target and control genotypes, tissue molecular and expression
analysis, photoacoustic microscopy, and inﬂammation challenge experi-
ments are available in SI Materials and Methods. The Animal Studies Com-
mittee of Washington University in St. Louis approved all animal care and
experimental procedures.
Fig. 5. HIF-1–mediated myeloid cell recruitment is abrogated in the absence
of VEGF. (A) Representative CD31/CD11b coimmunoﬂuorescence showing
marked temporal delay and diminution of stromal myeloid cell inﬁltration
in VEGFΔ mice compared with early and robust CD11b+ myeloid cell re-
cruitment inVEGFf/f counterparts. (B and C) Quantiﬁcation of stromal area
occupied by CD11b+ (B) (n = 3–4 mice per time point) and CD45+ cells (C; see
Fig. S5 for representative immunoﬂuorescent images) (n = 3–6 mice per time
point). Data analyzed as in Fig. 1: *P < 0.05, **P < 0.01, and ***P < 0.001.
(Scale bar: 200 μm.)
Fig. 6. 12-O-Tetradecanoylphorbol-13-acetate (TPA) treatment partially
rescues neovascularization and results in moderate VEGF induction. (A)
Quantiﬁcation of CD31(+) area in (n = 3–6 mice per time point) revealed
a twofold increase in neovascularization in TPA-treated VEGFΔ mice. (B)
Whole ear tissue ELISA for VEGF. A single dose of TPA in VEGFΔ mice pro-
duced a twofold increase in VEGF. In contrast, VEGF levels were not further
increased in TPA-treated VEGFf/f mice. (n = 3–6 mice per time point). Data
analyzed as in Fig. 1: *P < 0.05, **P < 0.01, and ***P < 0.001.
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Statistical Analysis. The data are reported as the mean ± SD. Data from DOX-
treated TetON-HIF-1:VEGFΔ or TetON-HIF-1VEGFf/f mice were compared ei-
ther with day 0 or NTG mice treated with DOX for the same interval by using
the unpaired Student t test (GraphPad Prism 5). There were 3–6 mice per
group unless otherwise indicated.
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